191 related articles for article (PubMed ID: 32451928)
21. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors.
Cives M; Partelli S; Palmirotta R; Lovero D; Mandriani B; Quaresmini D; Pelle' E; Andreasi V; Castelli P; Strosberg J; Zamboni G; Falconi M; Silvestris F
Sci Rep; 2019 Dec; 9(1):18614. PubMed ID: 31819132
[TBL] [Abstract][Full Text] [Related]
22. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
23. Genomic landscape of pancreatic neuroendocrine tumours: the International Cancer Genome Consortium.
Mafficini A; Scarpa A
J Endocrinol; 2018 Mar; 236(3):R161-R167. PubMed ID: 29321190
[TBL] [Abstract][Full Text] [Related]
24. Primary renal well-differentiated neuroendocrine tumour (carcinoid): next-generation sequencing study of 11 cases.
Pivovarcikova K; Agaimy A; Martinek P; Alaghehbandan R; Perez-Montiel D; Alvarado-Cabrero I; Rogala J; Kuroda N; Rychly B; Gasparov S; Michalova K; Michal M; Hora M; Pitra T; Tuckova I; Laciok S; Mareckova J; Hes O
Histopathology; 2019 Jul; 75(1):104-117. PubMed ID: 30851202
[TBL] [Abstract][Full Text] [Related]
25. Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours.
Samsom KG; Levy S; van Veenendaal LM; Roepman P; Kodach LL; Steeghs N; Valk GD; Wouter Dercksen M; Kuhlmann KFD; Verbeek WHM; Meijer GA; Tesselaar MET; van den Berg JG
Histopathology; 2021 Mar; 78(4):556-566. PubMed ID: 32931025
[TBL] [Abstract][Full Text] [Related]
26. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
Pea A; Hruban RH; Wood LD
Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
[TBL] [Abstract][Full Text] [Related]
27. Genome analysis identifies differences in the transcriptional targets of duodenal versus pancreatic neuroendocrine tumours.
Rico K; Duan S; Pandey RL; Chen Y; Chakrabarti JT; Starr J; Zavros Y; Else T; Katona BW; Metz DC; Merchant JL
BMJ Open Gastroenterol; 2021 Nov; 8(1):. PubMed ID: 34750164
[TBL] [Abstract][Full Text] [Related]
28. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine tumours in 2012: Insights into signalling pathways could individualize therapy.
Oberg K
Nat Rev Endocrinol; 2013 Feb; 9(2):70-2. PubMed ID: 23296177
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives.
Marini F; Giusti F; Brandi ML
Expert Rev Endocrinol Metab; 2021 Nov; 16(6):295-307. PubMed ID: 34554891
[TBL] [Abstract][Full Text] [Related]
31. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
[TBL] [Abstract][Full Text] [Related]
32. Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
Boora GK; Kanwar R; Kulkarni AA; Pleticha J; Ames M; Schroth G; Beutler AS; Banck MS
Cancer Genet; 2015; 208(7-8):374-81. PubMed ID: 26087898
[TBL] [Abstract][Full Text] [Related]
33. Relevance of neuroendocrine tumours models assessed by kinomic profiling.
Romano D
Ann Endocrinol (Paris); 2019 Jun; 80(3):144-148. PubMed ID: 31054767
[TBL] [Abstract][Full Text] [Related]
34. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours.
Singh RR; Patel KP; Routbort MJ; Aldape K; Lu X; Manekia J; Abraham R; Reddy NG; Barkoh BA; Veliyathu J; Medeiros LJ; Luthra R
Br J Cancer; 2014 Nov; 111(10):2014-23. PubMed ID: 25314059
[TBL] [Abstract][Full Text] [Related]
35. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.
Amato E; Molin MD; Mafficini A; Yu J; Malleo G; Rusev B; Fassan M; Antonello D; Sadakari Y; Castelli P; Zamboni G; Maitra A; Salvia R; Hruban RH; Bassi C; Capelli P; Lawlor RT; Goggins M; Scarpa A
J Pathol; 2014 Jul; 233(3):217-27. PubMed ID: 24604757
[TBL] [Abstract][Full Text] [Related]
36. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
[TBL] [Abstract][Full Text] [Related]
37. Proteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms.
Yang KC; Kalloger SE; Aird JJ; Lee MKC; Rushton C; Mungall KL; Mungall AJ; Gao D; Chow C; Xu J; Karasinska JM; Colborne S; Jones SJM; Schrader J; Morin RD; Loree JM; Marra MA; Renouf DJ; Morin GB; Schaeffer DF; Gorski SM
Cell Rep; 2021 Oct; 37(2):109817. PubMed ID: 34644566
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
Wang F; Xu X; Ye Z; Qin Y; Yu X; Ji S
Front Endocrinol (Lausanne); 2021; 12():691557. PubMed ID: 34220718
[TBL] [Abstract][Full Text] [Related]
39. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study.
Vijayvergia N; Boland PM; Handorf E; Gustafson KS; Gong Y; Cooper HS; Sheriff F; Astsaturov I; Cohen SJ; Engstrom PF
Br J Cancer; 2016 Aug; 115(5):564-70. PubMed ID: 27482646
[TBL] [Abstract][Full Text] [Related]
40. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
Chatani PD; Agarwal SK; Sadowski SM
Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
